美国全身麻醉剂市场规模、份额、趋势分析报告：按药物、途径途径、最终用途、应用、国家/地区、细分市场预测，2024-2030 年

美国全身麻醉剂市场成长与趋势：

根据 Grand View Research, Inc. 预测，到 2030 年，美国全身麻醉剂市场规模预计将达到 20.3 亿美元，2024 年至 2030 年复合年增长率为 2.8%。

这一增长主要是由手术数量的增加所推动的。美国麻醉医师协会 (ASA) 强调，由于人口老化、慢性病盛行率增加以及手术技术的进步，手术数量持续增加。美国疾病管制与预防中心 (CDC) 2024 年 2 月报告称，大约 1.29 亿美国人患有至少一种主要慢性疾病，例如癌症、心臟病、糖尿病或高血压。慢性病的高盛行率导致大量心血管和其他外科手术，从而导致对有效全身麻醉剂的需求增加。

麻醉技术的进步也是重要的驱动因素。REMIFENTANIL等超短效麻醉剂创新可以更好地控制麻醉深度并缩短恢復时间，从而改善患者的治疗效果并推动市场成长。此外，先进的输送系统和监测技术（包括自动麻醉输送系统）的发展透过提高准确性和安全性正在彻底改变麻醉实践。

监管的发展也扮演着重要角色。 FDA 对突破性疗法的快速核准途径有助于快速获得新的有效麻醉剂。例如，最近核准的新型缓释性麻醉剂ZYNRELEF™ 展示了监管进步如何支持创新产品的采用。

美国全身麻醉剂市场报告亮点

• 以药物来看，Propofol细分预计将在 2023 年占据市场主导地位，收益占有率将达到 25.4%，并且预计在预测期内将以 3.4% 的复合年增长率增长最快。
• 按途径途径划分，静脉注射在 2023 年占据最大收益占有率，为 63.1%，预计在预测期内将以 3.0% 的最快复合年增长率增长。
• 从应用来看，全膝关节关节重建和全髋置换术占据了市场主导地位，并占据了可观的收益占有率。
• 按最终用途划分，医院细分市场占据主导地位，到 2023 年，收益占有率将达到 67.2%。医院是需要全身麻醉的大型手术和复杂医疗程序的主要场所。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章美国全身麻醉剂市场变数、趋势、范围

• 市场体系展望
  • 母市场展望
  • 相关/附随市场展望
• 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
• 美国全身麻醉剂市场分析工具
  • 产业分析-波特五力分析
  • PESTEL分析

第四章美国全身麻醉剂市场：药物预估及趋势分析

• 美国全身麻醉剂市场：药物仪表板
• 美国全身麻醉剂市场：药物波动分析
• 美国全身麻醉剂市场：按药物分類的收益
• SEVOFLURANE
• Propofol
• Dexmedetomidine
• REMIFENTANIL
• DESFLURANE
• 咪达唑仑
• 其他的

第五章美国全身麻醉剂市场：给药途径预估及趋势分析

• 美国全身麻醉剂市场：给药途径仪表板
• 美国全身麻醉剂市场：给药途径变异分析
• 按管理途径的收益
• 静脉
• 吸入型

第六章美国全身麻醉剂市场：最终用途估计与趋势分析

• 美国全身麻醉剂市场：最终用途仪表板
• 美国全身麻醉剂市场：最终用途变化分析
• 按最终用途分類的收益
• 医院
• 门诊手术中心
• 其他的

第七章美国全身麻醉剂市场：应用估算与趋势分析

• 美国全身麻醉剂市场：应用仪表板
• 美国全身麻醉剂市场：应用变化分析
• 按使用情况分類的收益
• 心血管手术
  • 2018-2030 年心血管手术市场估计与预测
• 癌症
  • 2018-2030 年癌症市场估计与预测
• 一般外科
  • 2018-2030 年其他市场估计与预测
• 膝关节/髋关节置换术
  • 2018-2030 年其他市场估计与预测
• 其他的
  • 2018-2030 年其他市场估计与预测

第八章美国全身麻醉剂市场：按药物、给药途径的区域估计和趋势分析

• 区域仪表板
• 2018-2030年市场规模、预测趋势分析：

第9章 竞争格局

• 公司/竞争对手分类
• 供应商情况
  • 主要经销商及通路伙伴名单
  • 2023年主要企业市场占有率分析
  • Baxter International Inc.
  • AstraZeneca
  • AbbVie Inc.
  • B. Braun Melsungen AG
  • Fresenius SE &Co. KgaA
  • Pfizer
  • Hospira Inc.
  • Aspen Pharmacare Holdings Limited
  • Hikama Pharmaceuticals plc
  • Abbott Laboratories

U.S. General Anesthesia Drugs Market Growth & Trends:

The U.S. general anesthesia drugs market size is projected to reach USD 2.03 billion by 2030, and is anticipated to grow at a CAGR of 2.8% from 2024 to 2030, according to Grand View Research, Inc. The rising number of surgical procedures primarily drives this growth. The American Society of Anesthesiologists (ASA) highlights a consistent increase in surgeries, attributed to an aging population, the growing prevalence of chronic diseases, and advancements in surgical techniques. The CDC reported in February 2024 that approximately 129 million Americans have at least one major chronic disease, such as cancer, heart disease, diabetes, and hypertension. This high prevalence of chronic conditions necessitates numerous cardiovascular and other surgeries, which in turn drives the demand for effective general anesthesia drugs.

Advancements in anesthesia technology are another critical driver. Innovations such as ultra-short-acting anesthetics, like remifentanil, offer improved control over anesthesia depth and faster recovery times, enhancing patient outcomes and driving market growth. Additionally, the development of advanced delivery systems and monitoring technologies, including automated anesthesia delivery systems, has revolutionized anesthesia practices by improving precision and safety.

Regulatory developments also play a significant role. The FDA's expedited approval pathways for breakthrough therapies facilitate quicker access to new and effective anesthetics. For instance, the recent approval of ZYNRELEFTM, a novel extended-release anesthetic, illustrates how regulatory advancements support the introduction of innovative products.

U.S. General Anesthesia Drugs Market Report Highlights:

• Based on drug, the propofol segment dominated the market with a substantial revenue share of 25.4% in 2023 and is also expected to grow at the fastest CAGR of 3.4% during the forecast period, driven by its widespread use as a preferred agent for induction and maintenance of general anesthesia.
• Based on route of administration, the intravenous segment held the largest revenue share of 63.1% in 2023 and is also expected to grow at the fastest CAGR of 3.0% during the forecast period
• Based on application, the knee and hip replacements segment dominated the market, capturing a substantial revenue share.
• Based on end use, the hospitals segment dominated the market, capturing a substantial revenue share of 67.2% in 2023. Hospitals are the primary settings for major surgeries and complex medical procedures that require general anesthesia.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug
  • 1.2.2. Route of Administration
  • 1.2.3. End Use
  • 1.2.4. Application
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug Outlook
  • 2.2.2. Route of Administration
  • 2.2.3. End Use
  • 2.2.4. Application
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. U.S. General Anesthesia Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing Volume Of Surgical Procedures
    • 3.2.1.2. Advancements In Anesthesia Technology
    • 3.2.1.3. Regulatory Developments
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Regulatory and Compliance Challenges
    • 3.2.2.2. Adverse Effects and Safety Concerns
• 3.3. U.S. General Anesthesia Drugs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. U.S. General Anesthesia Drugs Market: Drug Estimates & Trend Analysis

• 4.1. U.S. General Anesthesia Drugs Market: Drug Dashboard
• 4.2. U.S. General Anesthesia Drugs Market: Drug Movement Analysis
• 4.3. U.S. General Anesthesia Drugs Market by Drug, Revenue
• 4.4. Sevoflurane
  • 4.4.1. Sevoflurane market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Propofol
  • 4.5.1. Propofol market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Dexmedetomidine
  • 4.6.1. Dexmedetomidine market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Remifentanil
  • 4.7.1. Remifentanil market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Desflurane
  • 4.8.1. Desflurane market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Midazolam
  • 4.9.1. Midazolam market estimates and forecasts 2018 to 2030 (USD Million)
• 4.10. Others
  • 4.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. General Anesthesia Drugs Market: Route of Administration Estimates & Trend Analysis

• 5.1. U.S. General Anesthesia Drugs Market: Route of Administration Dashboard
• 5.2. U.S. General Anesthesia Drugs Market: Route of Administration Movement Analysis
• 5.3. U.S. General Anesthesia Drugs Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
• 5.4. Intravenous
  • 5.4.1. Intravenous market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Inhaled
  • 5.5.1. Inhaled market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. General Anesthesia Drugs Market: End Use Estimates & Trend Analysis

• 6.1. U.S. General Anesthesia Drugs Market: End Use Dashboard
• 6.2. U.S. General Anesthesia Drugs Market: End Use Movement Analysis
• 6.3. U.S. General Anesthesia Drugs Market Estimates and Forecasts, By End Use, Revenue (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Ambulatory Surgical Centers
  • 6.5.1. Ambulatory Surgical Centers market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. General Anesthesia Drugs Market: Application Estimates & Trend Analysis

• 7.1. U.S. General Anesthesia Drugs Market: Application Dashboard
• 7.2. U.S. General Anesthesia Drugs Market: Application Movement Analysis
• 7.3. U.S. General Anesthesia Drugs Market Estimates and Forecasts, By Application, Revenue (USD Million)
• 7.4. Heart Surgeries
  • 7.4.1. Heart Surgeries market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Cancer
  • 7.5.1. Cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. General Surgery
  • 7.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Knee and hip replacements
  • 7.7.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Other
  • 7.8.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. U.S. General Anesthesia Drugs Market: Regional Estimates & Trend Analysis by Drug, Route of Administration, End Use and Application

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.2.1. U.S.
    • 8.2.1.1. Key country dynamics
    • 8.2.1.2. Regulatory framework/ reimbursement structure
    • 8.2.1.3. Competitive scenario
    • 8.2.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Vendor Landscape
  • 9.2.1. List of key distributors and channel partners
  • 9.2.2. Key company market share analysis, 2023
  • 9.2.3. Baxter International Inc.
    • 9.2.3.1. Company overview
    • 9.2.3.2. Financial performance
    • 9.2.3.3. Drug benchmarking
    • 9.2.3.4. Strategic initiatives
  • 9.2.4. AstraZeneca
    • 9.2.4.1. Company overview
    • 9.2.4.2. Financial performance
    • 9.2.4.3. Drug benchmarking
    • 9.2.4.4. Strategic initiatives
  • 9.2.5. AbbVie Inc.
    • 9.2.5.1. Company overview
    • 9.2.5.2. Financial performance
    • 9.2.5.3. Drug benchmarking
    • 9.2.5.4. Strategic initiatives
  • 9.2.6. B. Braun Melsungen AG
    • 9.2.6.1. Company overview
    • 9.2.6.2. Financial performance
    • 9.2.6.3. Drug benchmarking
    • 9.2.6.4. Strategic initiatives
  • 9.2.7. Fresenius SE & Co. KgaA
    • 9.2.7.1. Company overview
    • 9.2.7.2. Financial performance
    • 9.2.7.3. Drug benchmarking
    • 9.2.7.4. Strategic initiatives
  • 9.2.8. Pfizer
    • 9.2.8.1. Company overview
    • 9.2.8.2. Financial performance
    • 9.2.8.3. Drug benchmarking
    • 9.2.8.4. Strategic initiatives
  • 9.2.9. Hospira Inc.
    • 9.2.9.1. Company overview
    • 9.2.9.2. Financial performance
    • 9.2.9.3. Drug benchmarking
    • 9.2.9.4. Strategic initiatives
  • 9.2.10. Aspen Pharmacare Holdings Limited
    • 9.2.10.1. Company overview
    • 9.2.10.2. Financial performance
    • 9.2.10.3. Drug benchmarking
    • 9.2.10.4. Strategic initiatives
  • 9.2.11. Hikama Pharmaceuticals plc
    • 9.2.11.1. Company overview
    • 9.2.11.2. Financial performance
    • 9.2.11.3. Drug benchmarking
    • 9.2.11.4. Strategic initiatives
  • 9.2.12. Abbott Laboratories
    • 9.2.12.1. Company overview
    • 9.2.12.2. Financial performance
    • 9.2.12.3. Drug benchmarking
    • 9.2.12.4. Strategic initiatives

List of Tables

• Table 1 List Of Abbreviation
• Table 2 U.S. General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 3 U.S. General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 4 U.S. General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 5 U.S. General Anesthesia Drugs Market, Application, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 U.S. General Anesthesia Drugs Market: Market Outlook
• Fig. 10 Colorectal Surgery Competitive Insights
• Fig. 11 Parent market outlook
• Fig. 12 Related/ancillary market outlook
• Fig. 13 U.S. General Anesthesia Drugs Market Driver Impact
• Fig. 14 U.S. General Anesthesia Drugs Market Restraint Impact
• Fig. 15 U.S. General Anesthesia Drugs Market Strategic Initiatives Analysis
• Fig. 16 U.S. General Anesthesia Drugs Market: Drug Movement Analysis
• Fig. 17 U.S. General Anesthesia Drugs Market: Drug Outlook And Key Takeaways
• Fig. 18 Sevoflurane market estimates and forecast, 2018 - 2030
• Fig. 19 Propofol market estimates and forecast, 2018 - 2030
• Fig. 20 Dexmedetomidine market estimates and forecast, 2018 - 2030
• Fig. 21 Remifentanil market estimates and forecast, 2018 - 2030
• Fig. 22 Desflurane market estimates and forecast, 2018 - 2030
• Fig. 23 Midazolam market estimates and forecast, 2018 - 2030
• Fig. 24 Others market estimates and forecast, 2018 - 2030
• Fig. 25 U.S. General Anesthesia Drugs Market: Route of Administration Movement Analysis
• Fig. 26 U.S. General Anesthesia Drugs Market: Route of Administration Outlook And Key Takeaways
• Fig. 27 Intravenous market estimates and forecast, 2018 - 2030
• Fig. 28 Inhaled market estimates and forecast, 2018 - 2030
• Fig. 29 U.S. General Anesthesia Drugs Market: End Use Movement Analysis
• Fig. 30 U.S. General Anesthesia Drugs Market: End Use Outlook And Key Takeaways
• Fig. 31 Hospitals market estimates and forecast, 2018 - 2030
• Fig. 32 Ambulatory Surgical Centers market estimates and forecast, 2018 - 2030
• Fig. 33 Others market estimates and forecast, 2018 - 2030
• Fig. 34 U.S. General Anesthesia Drugs Market: Application Movement Analysis
• Fig. 35 U.S. General Anesthesia Drugs Market: Application Outlook And Key Takeaways
• Fig. 36 Heart Surgeries market estimates and forecast, 2018 - 2030
• Fig. 37 Cancer market estimates and forecast, 2018 - 2030
• Fig. 38 General Surgery market estimates and forecast, 2018 - 2030
• Fig. 39 Knee and hip replacements market estimates and forecast, 2018 - 2030
• Fig. 40 Other market estimates and forecast, 2018 - 2030
• Fig. 41 Market share of key market players- U.S. General Anesthesia Drugs Market